Disease Prevention Open Access Articles

Disease prevention is a list of measures taken to avoid diseases particularly infectious diseases. Disease prevention can be achieved by eliminating causative agents or by gaining more resistance towards that particular disease. Immunization is a well-known recommended method to get more resistance. We can also prevent many diseases by maintaining healthy diet and also through daily exercise. Some diseases can be prevented by undergoing some surgical treatments. Heart surgery is a best example to prevent many heart diseases. So, surgical treatments are also playing vital role in disease prevention. Present world is running towards many medicines and therapeutics to prevent almost all diseases.

High Impact List of Articles

The laparoscopic solution in a case of congenital cystic duct anomaly: a case report and review of the literature Kiril G. Kirov
Case Report: Clinical Investigation
The laparoscopic solution in a case of congenital cystic duct anomaly: a case report and review of the literature Kiril G. Kirov
Case Report: Clinical Investigation
The laparoscopic solution in a case of congenital cystic duct anomaly: a case report and review of the literature Kiril G. Kirov
Case Report: Clinical Investigation
The laparoscopic solution in a case of congenital cystic duct anomaly: a case report and review of the literature Kiril G. Kirov
Case Report: Clinical Investigation
The laparoscopic solution in a case of congenital cystic duct anomaly: a case report and review of the literature Kiril G. Kirov
Case Report: Clinical Investigation
The laparoscopic solution in a case of congenital cystic duct anomaly: a case report and review of the literature Kiril G. Kirov
Case Report: Clinical Investigation
Is social media suitable for patient recruitment? Wolfgang Eglmeier
Clinical Trail Perspective: Clinical Investigation
Is social media suitable for patient recruitment? Wolfgang Eglmeier
Clinical Trail Perspective: Clinical Investigation
Is social media suitable for patient recruitment? Wolfgang Eglmeier
Clinical Trail Perspective: Clinical Investigation
Is social media suitable for patient recruitment? Wolfgang Eglmeier
Clinical Trail Perspective: Clinical Investigation
Is social media suitable for patient recruitment? Wolfgang Eglmeier
Clinical Trail Perspective: Clinical Investigation
Is social media suitable for patient recruitment? Wolfgang Eglmeier
Clinical Trail Perspective: Clinical Investigation
Smoking causes adverse outcomes in cancer patients: addressing the evidence base through efficient design Graham W Warren
Commentary: Clinical Investigation
Smoking causes adverse outcomes in cancer patients: addressing the evidence base through efficient design Graham W Warren
Commentary: Clinical Investigation
Smoking causes adverse outcomes in cancer patients: addressing the evidence base through efficient design Graham W Warren
Commentary: Clinical Investigation
Smoking causes adverse outcomes in cancer patients: addressing the evidence base through efficient design Graham W Warren
Commentary: Clinical Investigation
Smoking causes adverse outcomes in cancer patients: addressing the evidence base through efficient design Graham W Warren
Commentary: Clinical Investigation
Smoking causes adverse outcomes in cancer patients: addressing the evidence base through efficient design Graham W Warren
Commentary: Clinical Investigation
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials. Stanislas Pol
Review: Clinical Trail Outcomes: Clinical Investigation
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials. Stanislas Pol
Review: Clinical Trail Outcomes: Clinical Investigation
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials. Stanislas Pol
Review: Clinical Trail Outcomes: Clinical Investigation
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials. Stanislas Pol
Review: Clinical Trail Outcomes: Clinical Investigation
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials. Stanislas Pol
Review: Clinical Trail Outcomes: Clinical Investigation
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials. Stanislas Pol
Review: Clinical Trail Outcomes: Clinical Investigation
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation

Clinical Investigation

Disease Prevention Open Access Articles

High Impact List of Articles

Relevant Topics in Clinical